Evaluate the Efficacy of Selenium for the Prevention of Chemotherapy-induced Mucositis During Autologous Stem Cell Transplantation.

• Status: Not yet recruiting
• Trial end date: 2022-05-01
• Target enrollment: 0
• Participant gender: All

Summary

Chemotherapy-induced mucositis is an important complication after autologous stem cell transplantation. It is mainly responsible for pain and dysphagia requiring opioids and artificial nutrition. It can also induce infectious complications. A few medication has demonstrated efficacy in this setting. It has been suggested that selenium can reduce the intensity of mucositis due to its antioxydant activity. The investigators therefore perform a randomized study to confirm this preliminary data.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital, Angers
• Treatments: Selenium

Criteria

Inclusion Criteria:

• Adult patients receiving autologous stem cell transplantation for lymphoma or myeloma.

• Signed informed consent.

Exclusion Criteria:

• Autologous stem cell transplantation for another medical condition than lymphoma or myéloma.

• Intolerance to selenium.

• High selenium levels before study.

• Pregnancy or patients breast-feeding.